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doi:10.1Objectives: Human subjects and Old World primates have high levels of antibody to galactose-a-1,3 galactose
b-1,4-N-acetylglucosamine (a-Gal). Commercially available bioprosthetic heart valves of porcine and bovine
origin retain the Gal antigen despite current processing techniques. Gal-deficient pigs eliminate this xenoanti-
gen. This study tests whether binding of human anti-Gal antibody effects calcification of wild-type and Gal-
deficient glutaraldehyde-fixed porcine pericardium by using a standard subcutaneous implant model.
Methods: Expression of a-Gal was characterized by lectin Griffonia simplicifolia–IB4 staining.
Glutaraldehyde-fixed pericardial disks from Gal-positive and Gal-deficient pigs were implanted into 12-day-
old Wistar rats and 1.5-kg rabbits with and without prelabeling with affinity-purified human anti-Gal antibody.
Calcification of the implants was determined after 3 weeks by using inductively coupled plasma spectroscopy.
Results: The a-Gal antigen was detected in wild-type but not Gal-deficient porcine pericardium.Wild-type disks
prelabeled with human anti-Gal antibody exhibited significantly greater calcification compared with that seen in
antibody-free wild-type samples (mean  standard error of the mean: 111  8.4 and 74  9.6 mg/g,
respectively; P ¼ .01). In the presence of anti-Gal antibody, a significantly greater level of calcification was de-
tected in wild-type compared with GTKO porcine pericardium (111  8.4 and 55  11.8 mg/g, respectively;
P ¼ .005). Calcification of Gal-deficient pericardium was not affected by the presence of anti-Gal antibody
(51  9.1 and 55  11.8 mg/g).
Conclusions: In this model anti-Gal antibody accelerates calcification of wild-type but not Gal-deficient glutaral-
dehyde-fixedpericardium.This study suggests that preformed anti-Gal antibodypresent in all patientsmight contrib-
ute to calcification of currently used bioprosthetic heart valves. Gal-deficient pigsmight become the preferred source
for new, potentially calcium-resistant bioprosthetic heart valves. (J Thorac Cardiovasc Surg 2011;141:269-75)Survival of pig-to-primate cardiac xenotransplantation has
improved through greater understanding of the mechanism
of rejection and the development of new technologies to
block xenograft rejection.1 Rejection of vascularized xeno-
grafts is dominated by antibody-mediated processes, in-
cluding complement-mediated injury and endothelial
cell activation, which results in xenograft rejection charac-
terized by widespread microvascular thrombosis and
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Gal), which has been identified as the predominant xeno-
graft rejection antigen present in the wild-type pig.2 All
mammalian species except human subjects and Old World
primates produce the a-Gal antigen.3 In pigs the a-Gal an-
tigen is present on glycoproteins and glycolipids, is ex-
pressed at high levels by vascular endothelial cells, and
might be present at up to 1011 epitopes per milligram of tis-
sue matrix.4 Human subjects and Old World primates pro-
duce anti-Gal antibody, which could be up to 1% of
circulating immunoglobulin (Ig) G and arises early in life
in response to stimulation by intestinal microflora.5
Methods have been developed to block or remove anti-
Gal antibody to prolong vascular xenograft survival6,7;
however, the advent of somatic cell nuclear transfer made
it possible to use homologous recombination in cultured
fibroblasts to disrupt the a-1,3 galactosyltransferase
(GGTA1) gene and thereby derive mutant pigs deficient in
the synthesis of the a-Gal antigen (GTKO pigs).8,9 These
GTKO pigs do not express the a-Gal antigen, and
vascular pig-to-primate xenografts with GTKO organs do
not induce an anti-Gal immune response.10 Because this
major xenogeneic antigen is eliminated from these animals,
they might be a useful source of material for the develop-
ment of new bioprosthetic heart valves (BHVs).rdiovascular Surgery c Volume 141, Number 1 269
Abbreviations and Acronyms
a-Gal ¼ galactose-a-1,3 galactose b-1,4-N-
acetylglucosamine
BHV ¼ bioprosthetic heart valve
GGTA1 ¼ a-1,3 galactosyltransferase
GSIB4 ¼ Griffonia simplicifolia–IB4
Ig ¼ immunoglobulin
LVAD ¼ left ventricular assist device
PBS ¼ phosphate-buffered saline




SBHVs are commonly produced from glutaraldehyde-fixed
porcine aortic valves or sewn from fixed bovine pericardium.
Such valves generally do not require anticoagulation and have
a low level of thrombogenicity. BHVs are used principally in
older patients because they are more durable in this popula-
tion and because BHV degeneration occurs more rapidly in
younger patients. BHV degeneration, which involves exten-
sive calcification, has been attributed to excess glutaralde-
hyde, mechanical failure, collagen degradation, and calcium
precipitation by residual lipids. Theremight also be an immu-
nologic mechanism or mechanisms that lead to valve degen-
eration because fixationmethods do not completely eliminate
device antigenicity11,12 and patients implanted with BHVs
exhibit increased levels of anti-Gal reactive antibody.13 In
this study we investigate the potential for anti-Gal antibody
to promote calcification using the subcutaneous implant
model in rats and rabbits. We compare the level of calcifica-
tion of wild-type and GTKO glutaraldehyde-fixed pericar-
diumwith and without exposure to human anti-Gal antibody.MATERIALS AND METHODS
Anti-Gal Antibody
Human anti-Gal antibody was affinity purified from human AB plasma
with a-Gal Sepharose columns (Nextran, Princeton, NJ).14 Antibody was
recovered from the column by using free a-Gal trisaccharide competition
and was dialyzed before storage at80C. For labeling-fixed porcine peri-
cardial disks, anti-Gal antibody (4 mg/mL) was diluted into phosphate-
buffered saline (PBS) and sterile filtered.
Calcium Determination
Calcium levels were determined by the Mayo Clinic trace metals labo-
ratory, Department of Laboratory Medicine and Pathology. In brief, dried
pericardium samples were weighed and extracted at 76C with concen-
trated nitric acid and 30% hydrogen peroxide. Samples were diluted in
1% HCl and loaded into an Optimas Inductively Coupled Plasma ICP
emission instrument. Calcium was measured at 317.9 nm and yttrium
at 371.0 nm as an internal control. A standard curve for calcium
(0–500 mg/mL) and linearity checks were performed for each analysis.
Lectin Stain
Leaflets from fresh porcine heart valves or commercial BHVs were em-
bedded in optimal cutting temperature material (OCT; Miles Laboratories,
Elkhart, Ind), snap-frozen in isopentane and dry ice, and cut on a cryostat
into 4-mm-thick sections. Sections were processed by using standard270 The Journal of Thoracic and Cardiovascular Surgmethods for histochemical staining. The a-Gal–specific lectin Griffonia
simplicifolia–IB4 (GSIB4) requires divalent cations for binding. GSIB4
conjugated to horseradish peroxidase (EY Laboratories, San Mateo, Calif)
was diluted to 2 mg/mL in Dulbecco’s PBS (with Ca2þand Mn2þ) with 1%
bovine serum albumin and incubated with the sections for 2 hours at 4C.
Lectin binding was visualized with 3,3’-diaminobenzidine staining
(Sigma–Aldrich Corp, St Louis, Mo).
Paraffin-embedded formalin-fixed tissue sections were deparaffinized
with 2 exchanges of Histo-Clear; rehydrated through a 100%, 95%, and
80% ethanol series; and rinsed in distilled water. Antigen retrieval was per-
formed by immersing slides in citrate buffer (10mmol/L sodium citrate and
0.05% Tween 20, pH 6.0) at 95C to 100C for 20 minutes and allowed to
cool to room temperature. Sections were rinsed in PBS and 0.05% Tween
20 and blocked with PBS and 1% bovine serum albumin. Fluorescein
isothiocyanate–conjugated GSIB4 was diluted as indicated above, and sec-
tions were stained at 4C for 2 hours, washed with PBS and 0.05% Tween
20, and examined with a Zeiss LSM51 confocal microscope. The specific-
ity of lectin staining was determined by competition with 10 mmol/L free
a-Gal trisaccharide before staining.
Pericardial Treatment and Implants
Pericardium from wild-type and GTKO pigs was fixed and stored in
0.6% glutaraldehyde. After cutting into 0.8-cm disks, the pericardium
was washed in sterile saline overnight before antibody staining. All disks
were incubated with affinity-purified human anti-Gal antibody (IgM and
IgG) at 4 mg/mL in PBS for 1 hour at 4C with gentle mixing. The density
of disks for antibody labeling was 2 disks per milliliter. Disks were washed
in an excess of sterile saline for 1 hour before implantation. After implan-
tation, unused disks were labeled with goat anti-human IgG and IgM to
document the level of antibody binding at the time of implantation.
Rat and Rabbit Implants
Twelve-day-old Wistar rats received subcutaneous implants of
glutaraldehyde-fixed disks with and without prelabeling with anti-Gal an-
tibody. Briefly, each recipient was initially anesthetized with ketamine and
xylazine andmaintained on 1% isoflurane. The skin was cleaned with 70%
alcohol and Betadine, and 4 subcutaneous incisions were made along the
dorsal surface, 2 per side. Disks were implanted smoothly against the
body musculature, and the incisions were closed with sutures. Rabbit im-
plantations were performed on 1.5-kg rabbits. The hair was shaved from
the dorsal surface, and the skin washed with Betadine. Five subcutaneous
incisions were made per side, disks were implanted against the body wall,
and the incisions were closed with sutures. In each instance a minimum of
10 (rats) or 40 (rabbits) disks were implanted and recovered for calcium de-
termination. All animals were housed and received humane care in accor-
dance with the standards established by the Institutional Animal Care and
Use Committee of the Mayo Clinic and Foundation and as described in
the ‘‘Guide for the care and use of laboratory animals’’ prepared by the
Institute of Laboratory Animal Resources and published by the National
Institutes of Health (publication no. 86-23, revised 1996).
Statistical Analysis
All data are presented as means standard errors of the mean. Compar-
isons between experimental groups were tested for significance with the
Student’s t test.RESULTS
Expression of a-Gal in Porcine Tissues
Expression of the a-Gal antigen was detected by using
fluorescein isothiocyanate– or horseradish peroxidase–con-
jugated GSIB4 lectin. High levels of lectin binding were de-
tected in the matrix components of fresh wild-type porcineery c January 2011
FIGURE 1. Comparison of GSIB4 staining of wild-type (WT; A–C) and GTKO (D–F) cardiac valves. A and D, Hematoxylin and eosin staining. B and E,
Staining with Griffonia simplicifolia-IB4 (GSIB4)–horseradish peroxidase (HRP). C and F, GSIB4–HRP staining in the presence of 10 mmol/L a-Gal tri-
saccharide. Under these conditions, there is minimal staining because soluble a-Gal blocks lectin binding to the tissue.




Sheart valves (Figure 1, A and B). Staining appeared uniform
across the valve and was specific for the a-Gal carbohydrate
because lectin binding was largely eliminated when the a-
Gal binding sites of GSIB4 were blocked by competition
with soluble a-Gal trisaccharide (Figure 1, C). In contrast,
no specific staining was detected on fresh porcine heart
valves from GTKO pigs (Figure 1, D-F). The a-Gal antigen
is also expressed in the matrix of other tissues that might be
used for the development of bioprosthetic devices. Intense
staining of formalin-fixed porcine ligaments (Figure 2, A
and B), tendons (Figure 2, C and D), and pericardia
(Figure 2, E and F) was evident in wild-type tissues.
Staining was a-Gal specific because competition with solu-
ble a-Gal trisaccharide effectively blocked GSIB4 binding
(Figure 2, B, D,and E inserts). Tissues from GTKO pigs
did not exhibit appreciable GSIB4 binding (Figure 2, H, J,
and L). After extensive fixation in 0.6% glutaraldehyde,
the a-Gal antigen remains accessible, as evidenced by lectin
binding to wild-type but not GTKO porcine pericardium
(Figure 3).
a-Gal Expression in Commercial Devices
Bovine- and porcine-derived clinical BHVs were specif-
ically stained with GSIB4 (Figure 4). The lectin stainingThe Journal of Thoracic and Caindicated expression of a-Gal was broadly distributed
across the BHV matrix and was similar to that observed
in fresh and glutaraldehyde-fixed porcine valves.
Anti-Gal Antibody Accelerates Calcification
To determine whether preformed anti-Gal antibody
present in BHV recipients affected calcification of
glutaraldehyde-fixed pericardium, we labeled wild-type
and GTKO fixed pericardium with affinity-purified human
anti-Gal antibody before implantation into juvenile rats or
rabbits. Disks for implantation were processed as a batch,
and after implantation, the remaining disks were stained to
document the extent of antibody binding at the time of im-
plantation. Wild-type fixed pericardium bound anti-Gal
IgM and IgG and exhibited strong peroxidase staining
(Figure 5, A). Little or no staining was evident on fixed
GTKO pericardium. Wild-type disks coated with antibody
and implanted into 12-day-old Wistar rats for 20 days
showed extensive calcification on explants (Figure 5, B).
Significantly increased calcification was evident in wild-
type tissue incubated with anti-Gal antibody compared
with that seen in the same tissue without antibody or com-
paredwithGTKO tissuewith or without antibody. Calcifica-
tion of GTKO samples was not affected by incubation withrdiovascular Surgery c Volume 141, Number 1 271
FIGURE 2. Comparison of wild-type and GTKOGal expression. A–F,Wild-type porcine tissue. G–L, GTKO porcine tissue. The figure shows hematoxylin
and eosin (HþE) and fluorescein isothiocyanate–Griffonia simplicifolia-IB4 (FITC-GSIB4) staining of porcine ligaments (A and G), tendons (C and I), and
pericardia (E and K). The inserts in B, D, and F show wild-type FITC-GSIB4 staining in the presence of a-Gal trisaccharide.




Santi-Gal antibody and tended to be less than seen in wild-
type samples under all conditions in the rat model. The
same experimentwas also performedwith subcutaneous im-
plants in rabbits (Figure 5, C). There was significantly
greater calcification of wild-type glutaraldehyde-fixed
porcine pericardium prelabeled with anti-Gal antibody
compared with wild-type pericardium without antibody or
GTKO pericardium with or without antibody.FIGURE 3. The Gal antigen is present after glutaraldehyde fixation in
wild-type but not GTKO pericardium. Fluorescein isothiocyanate–Griffo-
nia simplicifolia-IB4 staining of 0.6% glutaraldehyde-fixed wild-type
(A) or GTKO (B) pericardium is shown.
272 The Journal of Thoracic and Cardiovascular SurgCalcification of the explanted pericardium, as judged
based on results of von Kossa staining, was largely confined
to the pericardial disc and was generally not present in
encapsulating cells. There was little evidence of cellular
infiltration of the pericardium (Figure 5, D–F).
DISCUSSION
BHVs derived from animal tissues have been clinically
used for more than 50 years. They are the preferred implants
for older patients because they have a low level of thrombo-
genicity and generally do not require anticoagulation. In
younger patients, however, BHVs exhibit a more rapid
rate of degeneration. This degenerative process is not fully
understood but is a multifaceted process including an in-
duced immunologic response to the implant. BHVs as
a component of left ventricular assist devices (LVADs)
have been temporarily implanted into younger patient pop-
ulations and might offer unique insight into the early immu-
nologic response. Khan and colleagues,15 showed, in the
absence of valve calcification, host tissue overgrowth, or
valve endocarditis, very early binding and progressive infil-
tration of CD68þmononuclear cells mainly on the nonflow
sinus surface of BHVs recovered from implanted LVADs.
This macrophage adhesion was detected in BHVs recovered
after only 7 days of implantation, increased over time, and
was associated with a progressive development of thrombus
formation and cystic spaces in all valves. These changes
were consistent with other studies16 that detected macro-
phage binding to the nonflow surface and IgG and comple-
ment deposition within the matrix after 37 days. These early
inflammatory changes could result secondarily from tearing
caused by mechanical or hemodynamic forces. Alterna-
tively, Fc receptor–mediated antibody binding of macro-
phages might initiate an inflammatory response, which
leads to collagen degradation, structural weakening, and
leaflet tearing. We note that the immunologic response of
LVAD recipients might not be identical to that of older
patients with implanted bioprosthetic valves. Theseery c January 2011
FIGURE 4. Griffonia simplicifolia-IB4 (GSIB4) staining of commercial bovine and porcine bioprosthetic valve devices. A, Hematoxylin and eosin stain-
ing. B, Staining of bovine devices with GSIB4–horseradish peroxidase (HRP) and of porcine devices with GSIB4–fluorescein isothiocyanate (FITC). C,
Staining of bovine devices with GSIB4-HRP and of porcine devices with GSIB4-FITC in the presence of 10 mmol/L soluble a-Gal trisaccharide. Under
these conditions, lectin binding to the a-Gal carbohydrate is effectively blocked.




Sdifferences might accelerate the inflammatory response in
LVAD recipients. Still, antibody binding to BHVs and the
potential for antibody-directed inflammatory reactions in
patients with BHVs remains a possibility. In that respect it
is important to note that an induced anti-Gal antibody
response has been observed in BHV recipients.13
In this report we show that a well-characterized and uni-
versal human preformed antibody specificity, anti-Gal, is
sufficient to accelerate calcification of glutaraldehyde-
fixed a-Gal–positive pericardium in both rat and rabbit sub-
cutaneous implant models. We further show that
glutaraldehyde-fixed pericardium from GTKO pigs does
not bind anti-Gal antibody and shows significantly lower
levels of calcification in these models. Our results are a sig-
nificant extension of previous work that demonstrated that
disks incubated with graft-specific antibody exhibited ac-
celerated calcification11 because in our case anti-Gal anti-
body is preformed and requires no immunization.
Although addition of antibody directly to the pericardium
might overestimate its effects on calcification, our results
indicate the potential for preformed antibody-directed in-
flammation as an immunologic mechanism to initiate calci-
fication. The rat subcutaneous implant model is an
inexpensive, reliable preclinical testing method used to as-
sess the effect of new manufacturing techniques to prevent
calcification. Processing techniques that reduce calcifica-
tion in this model have led to improved commercial
BHVs, but the results of this model do not always reflect
the outcomes in patients. Functional testing of new BHVsThe Journal of Thoracic and Cawith full blood exposure is generally performed in juvenile
sheep, in which BHV calcification can be observed within
3 to 6 months.17,18 Sheep produce the a-Gal antigen,
however, and therefore the affects of the anti-Gal antibody
cannot be determined in this model. Further examination of
the role of anti-Gal antibody in BHV calcification with full
exposure to blood could be performed by using implanta-
tion into Gal-deficient pigs. The slow rate of calcification,
expense, and ethical considerations generally preclude test-
ing new BHVs in nonhuman primates.
This study cannot directly link the affects of anti-Gal an-
tibody in the subcutaneous model to macrophage adhesion
and valve degeneration in patients with LVADs, but it does
confirm previous reports that device-specific antibody can
increase calcification11 and importantly demonstrates that
this can occur with preformed antibody specificity and
does not necessarily require sensitization. The historic ex-
perience with the rat subcutaneous model and our results
suggest that processes or materials which limit antibody
binding to BHVs will help to prevent calcification.
Expression of the a-Gal antigen in GTKO pigs has been
characterized in a variety of tissues, with emphasis on vas-
cular organs. We show, using GSIB4 staining, a high level
of a-Gal expression in the matrix of the pericardia, liga-
ments, and tendons of wild-type tissues and an absence
of expression in corresponding GTKO tissues. These obser-
vations are consistent with the results of Stone and
coworkers,4 who used a competitive enzyme-linked immu-
nosorbent assay to show the presence of up to 1011 Galrdiovascular Surgery c Volume 141, Number 1 273
FIGURE 5. Implantation and calcification of glutaraldehyde-fixed porcine pericardium with and without anti-Gal antibody binding. A, Whole pericardial
disks stained at the time of implantation with goat anti-human immunoglobulin (Ig)G and IgM to detect the binding of anti-Gal antibody. Lanes 1 and 3 show
specific staining for IgG (top) and IgM (bottom) onwild-type (WT) andGTKOdisks, respectively. Lanes 2 and 4 show background bindingwith only the goat
anti-human IgG (top) or IgM (bottom). B, Calcification of wild-type (black bars) and GTKO (white bars) pericardium 20 days after subcutaneous implan-
tation into 12-day-old rats. C, Calcification of wild-type (black bars) and GTKO (white bars) pericardium 20 days after subcutaneous implantation into
1.5-kg rabbits. Pericardial disks were implanted without exposure to human anti-Gal antibody (None) or after incubation with human anti-Gal antibody
(Human anti-Gal). Error bars represent the standard error of the mean. D and F, Representative von Kossa staining of explanted pericardium. D, Wild-
type disc preincubated with anti-Gal antibody before implantation. E, Wild-type disc without anti-Gal antibody before implantation. F, GTKO disc without
anti-Gal antibody before implantation. Von Kossa staining of calcium (black) is largely confined to the pericardium (p) and is absent in the eosin-stained
encapsulating cells (e).




Sepitopes per milligram of porcine tendon. We have investi-
gated the antigenicity of GTKO endothelial cell antigens af-
ter cardiac xenotransplantation.19 Although we cannot
exclude that additional carbohydrate antigen might be de-
tected by non-Gal antibodies in human subjects and nonhu-
man primates, it appears that the majority of non-Gal
antibodies are directed to common porcine proteins. The
antigenicity of these protein antigens is expected to be
strongly affected by glutaraldehyde cross-linking. We also
note that the a-Gal antigen has been used to augment the ef-
fectiveness of vaccines in which it enhances immune re-
sponses by increasing the formation and transport of
antigen complexes to lymph nodes for processing by274 The Journal of Thoracic and Cardiovascular Surgantigen-presenting cells.20 In this context the elimination
of this antigen might further reduce the antigenicity of
BHVs. Our observation of enhanced calcification when
anti-Gal antibody is bound to fixed pericardium suggests
that the absence of this antigen in tissue relevant for engi-
neering bioprosthetic devices is advantageous and that ma-
terials from GTKO pigs might make a significant
contribution to the development of improved bioprosthetic
devices, including BHVs.
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SDiscussion
Dr R. Duane Davis (Durham, NC). Chris, my congratulations.
First of all, let me just put it in perspective. You are demonstrating
that it is sufficient to have anti-Gal to cause this injury and calci-The Journal of Thoracic and Ca
/Bfication, and therefore it does really raise the following question:
Can we have a better biologic valve? That is incredibly important.
You did game the system a little bit. We know that there are a lot
of non-Gal anti-swine or other antibodies present, and you did not
use those in this experiment. That has a lot of variability. It can be
as little as 5% of the anti-swine antibody, or it can be as high as
35%. What happens when you use those antibodies in this model?
Dr McGregor. Clearly there are multiple non-Gal antibodies,
as you say, of variable quantities, somewhere up to 20%. We
started by dealing with the major antibody, which was 80% of
the bulk. We had to start somewhere. Do non-Gal antibodies mat-
ter? I am sure they do, but I do not think that we have sufficiently
defined their specificity as of this time. The major effort in our lab-
oratory now is to identify and specify those non-Gal antibodies so
that we can eliminate them by further genetic alteration of the pig.
They are important, but they are probably at the 20% level, as you
say.
Dr Davis. Let me kind of follow this up in terms of—you have
this model, which obviously it is not putting it into the blood. Is
there a way that we can actually test this in vivo in an animal
model, or do we just need to go to human applications?
Dr McGregor. That is a wonderful and very important ques-
tion. The animal models are all flawed, and we have known it
for a long time. The rat model is simply the best we have. Over
40 years it has correlated not unreasonably with subsequent clini-
cal performance in terms of improvement of processing. The sheep
model, because of the Gal issue, of course, is not applicable.
We currently have a number of nonhuman primates with Gal-
positive and Gal-negative biological mitral valves in place. But
this study takes an extraordinary length of time, and I am not con-
vinced it is going to give us the answers because we might have to
run them for up to 10 years. The preponderance of evidence now is
so powerful that my own belief is that we should go to a clinical
trial in young patients using these Gal knockout tissues because
there is no downside and because the potential upside is so impor-
tant that I think the evidence suggests we should go ahead at this
time.
Dr Davis. I really could not agree with you more on that. The
aspect now that you know that there is non-Gal antibody—and
in this situation you do not need to necessarily have tissues that
have ongoing expression per se—are there ways that you can
manipulate these Gal knockout tissues to make them appear to
function better because of the other immunologic potential injuries
that they could have?
Dr McGregor. Clearly the amount of antigenic tissue in any
heart valve is in part determined by the intensity and durability
of pretreatment and also affected by the treatment that any recip-
ient would receive. Therefore in several of these studies, for exam-
ple, steroid therapy diminished the antigenicity. That is not
something we would want to do in patients, but I think with pro-
cessing, there are always going to be areas where we can improve
in terms of residual antigenicity. The question is this: Will we pay
a price chemically in terms of collagen cross-linking and so forth.rdiovascular Surgery c Volume 141, Number 1 275
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